Our data demonstrating specific binding of the engineered variants to tumor cells positive for MSLN, followed by subsequent internalization of the engineered Fn3 proteins, establishes the potential for further development of MSLN-targeting Fn3 proteins for a variety of clinically relevant applications in diagnosis and therapy. This evidence concerns the gene MSLN and neoplasm.